Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Sensitive Ovarian Carcinoma”

222 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 222 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Study completedNCT00230542
What this trial is testing

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute 44
Testing effectiveness (Phase 2)Ended earlyNCT00247988
What this trial is testing

Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
University of Saskatchewan 38
Testing effectiveness (Phase 2)Ended earlyNCT03891576
What this trial is testing

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Mario Negri Institute for Pharmacological Research 83
Testing effectiveness (Phase 2)Study completedNCT02584465
What this trial is testing

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Who this might be right for
Ovarian Carcinoma
ARCAGY/ GINECO GROUP 68
Testing effectiveness (Phase 2)Looking for participantsNCT07024784
What this trial is testing

Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Who this might be right for
Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube Cancer+1 more
AbbVie 377
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06081595
What this trial is testing

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Who this might be right for
Relapsed Ovarian Cancer
Jin Li 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07454018
What this trial is testing

Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian CancerPlatinum-sensitive Ovarian Cancer
The First Affiliated Hospital of Soochow University 45
Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Early research (Phase 1)Study completedNCT01314105
What this trial is testing

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal Neoplasms
Boehringer Ingelheim 19
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Post-approval studies (Phase 4)Ended earlyNCT02035345
What this trial is testing

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

Who this might be right for
Recurrent Ovarian CancerPlatinum Sensitive Ovarian Cancer
Massachusetts General Hospital 15
Testing effectiveness (Phase 2)Study completedNCT00316173
What this trial is testing

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerNeoplasms, Ovarian
GlaxoSmithKline 77
Testing effectiveness (Phase 2)UnknownNCT05158062
What this trial is testing

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
Carcinoma, Ovarian Epithelial
Kosei Hasegawa, MD, PhD 35
Not applicableStudy completedNCT02262273
What this trial is testing

OSCA - Olaparib Standard of CAre Study

Who this might be right for
Platinum-sensitive Recurrent Serous Ovarian Cancer
AstraZeneca 2,123
Testing effectiveness (Phase 2)Study completedNCT00318370
What this trial is testing

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Morphotek 58
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Large-scale testing (Phase 3)UnknownNCT00532194
What this trial is testing

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Medical Research Council 486
Testing effectiveness (Phase 2)Study completedNCT01611558
What this trial is testing

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

Who this might be right for
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Bristol-Myers Squibb 40
Testing effectiveness (Phase 2)Study completedNCT03759587
What this trial is testing

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 19
Load More Results